Dimensional Fund Advisors LP Increases Stock Position in Dyne Therapeutics, Inc. $DYN

Dimensional Fund Advisors LP lifted its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 870.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 951,589 shares of the company’s stock after purchasing an additional 853,515 shares during the period. Dimensional Fund Advisors LP’s holdings in Dyne Therapeutics were worth $17,244,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DYN. Creative Planning raised its position in shares of Dyne Therapeutics by 6.8% during the third quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after buying an additional 986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Dyne Therapeutics by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after acquiring an additional 1,440 shares during the last quarter. Hilton Head Capital Partners LLC purchased a new position in Dyne Therapeutics during the first quarter valued at $26,000. Caxton Associates LLP grew its stake in Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after acquiring an additional 1,627 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its holdings in Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Brian S. Posner acquired 2,000 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, June 8th. The stock was bought at an average price of $16.94 per share, with a total value of $33,880.00. Following the completion of the purchase, the director directly owned 24,500 shares of the company’s stock, valued at approximately $415,030. This represents a 8.89% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jason P. Rhodes sold 297,211 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the completion of the transaction, the director directly owned 2,962 shares in the company, valued at approximately $68,896.12. The trade was a 99.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders bought 9,000 shares of company stock worth $156,800 and sold 1,558,819 shares worth $34,385,234. Company insiders own 9.46% of the company’s stock.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $26.25 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. Dyne Therapeutics, Inc. has a 1-year low of $10.78 and a 1-year high of $27.09. The firm has a market capitalization of $4.90 billion, a P/E ratio of -7.88 and a beta of 1.07. The company’s 50-day moving average is $22.00 and its 200 day moving average is $19.18.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Research analysts forecast that Dyne Therapeutics, Inc. will post -3.37 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on DYN. TD Cowen assumed coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating for the company. Sanford C. Bernstein lifted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Royal Bank Of Canada increased their price target on Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Finally, Morgan Stanley cut their price target on Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.42.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.